Mice without uPA, tPA, or plasminogen genes are resistant to experimental choroidal neovascularization

被引:45
作者
Rakic, JM [1 ]
Lambert, V
Munaut, C
Bajou, K
Peyrollier, K
Alvarez-Gonzalez, ML
Carmeliet, P
Foidart, JM
Noël, A
机构
[1] Univ Hosp, Dept Ophthalmol, B-4000 Liege, Belgium
[2] Univ Liege, Lab Tumor & Dev Biol, Liege, Belgium
[3] Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium
关键词
D O I
10.1167/iovs.02-0809
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE. To evaluate the presence and potential involvement of members of the plasminogen/plasminogen activator (Plg/PA) system in the exudative form of age-related macular degeneration (AMD). METHODS. The expression of PA members mRNA was evaluated in human and experimental choroidal neovascularization (CNV) by RT-PCR. The presence and activity of PA was studied by immunofluorescence and in situ zymography. The influence of endogenous plasminogen (Plg), urokinase (uPA), tissue type plasminogen activator (tPA), and uPA receptor (uPAR) was explored in single-gene-deficient mice in a model of laser-induced CNV. RESULTS. Members of the Plg/PA system were present both in human and murine CNV. The absence of Pig, uPA, or tPA significantly decreased the development of experimental CNV compared with wild-type or uPAR-deficient mice. This effect could be attributable, partly to a modulation of matrix metalloproteinase activity, but also to an accumulation of fibrinogen-fibrin in the laser-induced wounds. CONCLUSIONS. Together with previous work done by the authors, this study indicates that choroidal neovascularization is extremely sensitive to the modulation of Plg/PA system activity. This may provide a new strategy for the treatment of exudative AMD.
引用
收藏
页码:1732 / 1739
页数:8
相关论文
共 37 条
[1]  
Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO
[2]  
2-Z
[3]   The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin:: Implications for antiangiogenic strategies [J].
Bajou, K ;
Masson, V ;
Gerard, RD ;
Schmitt, PM ;
Albert, V ;
Praus, M ;
Lund, LR ;
Frandsen, TL ;
Brunner, N ;
Dano, K ;
Fusenig, NE ;
Weidle, U ;
Carmeliet, G ;
Loskutoff, D ;
Collen, D ;
Carmeliet, P ;
Foidart, JM ;
Noël, AS .
JOURNAL OF CELL BIOLOGY, 2001, 152 (04) :777-784
[4]   Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization [J].
Bajou, K ;
Noël, A ;
Gerard, RD ;
Masson, V ;
Brunner, N ;
Holst-Hansen, C ;
Skobe, M ;
Fusenig, NE ;
Carmeliet, P ;
Collen, D ;
Foidart, JM .
NATURE MEDICINE, 1998, 4 (08) :923-928
[5]   Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis [J].
Bergers, G ;
Brekken, R ;
McMahon, G ;
Vu, TH ;
Itoh, T ;
Tamaki, K ;
Tanzawa, K ;
Thorpe, P ;
Itohara, S ;
Werb, Z ;
Hanahan, D .
NATURE CELL BIOLOGY, 2000, 2 (10) :737-744
[6]  
BERMAN M, 1982, INVEST OPHTH VIS SCI, V22, P191
[7]  
Blasi F, 1999, THROMB HAEMOSTASIS, V82, P298
[8]   Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency [J].
Bugge, TH ;
Kombrinck, KW ;
Flick, MJ ;
Daugherty, CC ;
Danton, MJS ;
Degen, JL .
CELL, 1996, 87 (04) :709-719
[9]  
Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO
[10]  
2-H